Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

T1978000

Tricaprylin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Glycerin-tricaprylat, 1,2,3-Tricapryloyl-glycerin, 1,2,3-Trioctanoylglycerin, Glycerin-trioctanoat, Tricaprylin, Trioctanoin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Lineare Formel:
[CH3(CH2)6COOCH2]2CHOCO(CH2)6CH3
CAS-Nummer:
538-23-8
Molekulargewicht:
470.68
Beilstein:
1717202
MDL-Nummer:
MFCD00036236
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329826698
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

tricaprylin

Hersteller/Markenname

EDQM

bp

233 °C/1 mmHg (lit.)

Dichte

0.956 g/mL at 20 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

−20°C

SMILES String

CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC

InChI

1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3

InChIKey

VLPFTAMPNXLGLX-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Tricaprylin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

nwg

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

vibrant-m

Y0000794

Glycerin-monocaprylat

Triolein European Pharmacopoeia (EP) Reference Standard

Y0001113

Triolein

Supelco

Supelco

17810

Triglycerid-Mischung

Trimyristin European Pharmacopoeia (EP) Reference Standard

T2500100

Trimyristin

Supelco

Supelco

17811-1AMP

Lipidstandards: Triglycerid-Mischungen

Glycerintristearat ≥99%

Sigma-Aldrich

T5016

Glycerintristearat

Ken-Ichi Ogawara et al.
Journal of pharmaceutical sciences, 106(4), 1143-1148 (2017-01-09)
To develop a safer and more potent paclitaxel (PTX) formulation, we prepared various oil-in-water emulsions by using egg phosphatidylcholine, Tween 80, and a mixture of triglycerides with different fatty acid chain lengths as the cosurfactant, surfactant, and oil phase component
Sung Yong Lee et al.
Journal of biomedical science, 26(1), 41-41 (2019-05-28)
Endoplasmic reticulum stress has a profound effect on cancer cell proliferation and survival, and also has the capacity to activate cells of the adaptive immune system. Multimodal treatment methods that utilize and combine conventional cancer therapies with antigen-specific immunotherapies have
Li Huang et al.
Experimental animals, 68(3), 301-306 (2019-03-15)
Inflammation-related animal model is necessary to better understanding the association of inflammation with tumorigenesis. Although mouse models of inflammation-related lung tumorigenesis on A/J mice strain have been set up in previous study, there is no report on the model on
Ada W Y Leung et al.
Pharmaceutics, 11(3) (2019-03-20)
Liposomes are considered one of the most successful drug delivery systems (DDS) given their established utility and success in the clinic. In the past 40⁻50 years, Canadian scientists have made ground-breaking discoveries, many of which were successfully translated to the
Qi Zhang et al.
Oncotarget, 8(42), 72447-72456 (2017-10-27)
Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.